Alliance For Clinical Trials In Oncology

This study looks at whether men with metastatic prostate cancer that responds extremely well to hormone therapy can safely take a break from treatment. The goal is to see if their testosterone levels can recover and how long they can stay off therapy without the cancer worsening.…

This study tests whether adding two targeted drugs (encorafenib and cetuximab) after standard surgery and chemotherapy can lower the chance of cancer coming back in people with a specific genetic type of stage II/III colon cancer (BRAF V600E). Participants either receive the drug…

This study compares two treatments for people with a specific type of brain tumor (anaplastic or low-grade glioma with 1p/19q co-deletion). Both groups receive radiation therapy, but one group also gets the drug temozolomide during and after radiation, while the other gets a diff…

This study tests whether giving chemotherapy both before and after surgery (perioperative) works better than only after surgery (adjuvant) for people with pancreatic cancer that can be removed. About 358 participants will receive a combination of common chemo drugs. The goal is t…

This study compares a three-drug chemotherapy combination (FOLFIRINOX) against standard two-drug combinations (FOLFOX or CAPOX) after radiation in people with stage II or III rectal cancer. The goal is to see if the stronger regimen leads to a complete disappearance of the tumor,…

This study is for people with a rare type of blood cancer called peripheral T-cell lymphoma that hasn't been treated yet. It compares standard chemotherapy alone versus adding either duvelisib or CC-486 to the chemo. The goal is to see if these added drugs can improve the chance …

This phase 3 trial tests whether adding tucatinib to the standard drug T-DM1 can better prevent HER2-positive breast cancer from returning in high-risk patients. About 1,056 participants who still have cancer after initial treatment will receive either T-DM1 alone or T-DM1 plus t…

This phase 3 trial tests whether adding high-dose vitamin D3 to standard chemotherapy and a targeted drug (bevacizumab) helps people with metastatic colorectal cancer live longer without their disease getting worse. The study includes 455 adults whose cancer has spread and who ha…

This study compares low-dose tamoxifen to standard hormone therapy (aromatase inhibitors) in postmenopausal women with low-risk, hormone-positive early-stage breast cancer. The goal is to see if low-dose tamoxifen works as well at preventing cancer return while possibly having fe…

This study tests enzalutamide, a drug already approved for other cancers, in people with a certain type of salivary gland cancer that has spread or cannot be removed. The goal is to see if the drug can shrink tumors by at least 30% in at least 20% of participants. About 46 adults…

This study tests a combination of two chemotherapy drugs, gemcitabine and cisplatin, in people with muscle-invasive bladder cancer. The goal is to see if patients whose tumors have certain gene changes (DDR alterations) can avoid bladder removal and keep their bladder cancer-free…

This study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs (like pembrolizumab or nivolumab) after about a year instead of continuing indefinitely. The goal is to see if stopping early leads to similar survival rates while reducing side ef…

This study compares two treatments for a rare type of brain lymphoma: high-dose chemotherapy followed by a stem cell transplant versus standard chemotherapy alone. The goal is to see which approach better delays cancer progression. 113 newly diagnosed patients aged 18-75 are part…

This study tests whether a shorter course of radiation (hypofractionated) after mastectomy works as well as standard radiation to prevent breast cancer from coming back. About 900 people with stage II to IIIA breast cancer took part. The shorter schedule aims to cause fewer side …

This study compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combination (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer that has spread to other parts of the body. Only patien…

This study compares two treatments for advanced dedifferentiated liposarcoma, a rare cancer. One group gets palbociclib alone, the other gets palbociclib plus cemiplimab. The goal is to see if the combination helps stop cancer growth better than the single drug. About 77 adults w…

This study looks at two ways of giving radiation after surgery to remove cancer that has spread to the brain. One method gives a single, strong dose of radiation, while the other gives several smaller doses over time. The goal is to see which approach better prevents the cancer f…

This study tests a technique called axillary reverse mapping (ARM) during breast cancer surgery to see if it can prevent lymphedema, a painful and chronic arm swelling. About 534 women with early-stage breast cancer will be followed for 3 years. The goal is to find out if mapping…

This phase 3 study tests whether a combination of two hormone-blocking drugs (fulvestrant and anastrozole) works better than anastrozole alone to shrink estrogen receptor-positive breast cancer before surgery. About 1,473 postmenopausal women with stage II or III breast cancer wi…

This study tests whether adding rucaparib to standard enzalutamide treatment helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 participants will receive either the combination or enzalutamide alone. The goal is to see if t…

This study tests whether genetic testing can help doctors choose the right drug for people whose cancer has spread to the brain. Researchers will look for specific gene changes in tumor samples and then give patients a targeted medication matched to their mutation. The goal is to…

This study tested whether adding everolimus to the standard drug sorafenib helps people with a rare and advanced type of thyroid cancer called Hurthle cell cancer that no longer responds to radioactive iodine. The trial included 35 adults with measurable tumors. Researchers compa…

This study tests whether adding cetuximab to avelumab helps people with advanced skin squamous cell carcinoma live longer without their cancer getting worse. About 60 participants will receive either avelumab alone or avelumab plus cetuximab. The goal is to see if the combination…

This study compares a new treatment that combines a targeted drug (inotuzumab) with standard chemotherapy against chemotherapy alone for older adults with B-cell acute lymphoblastic leukemia or lymphoma. The targeted drug works like a smart bomb, attaching to cancer cells and del…

This study tests whether a natural substance called GM1 can prevent or reduce nerve damage (pain, numbness, tingling in hands and feet) caused by the chemotherapy drug paclitaxel in people with metastatic breast cancer. About 98 participants will receive either GM1 or a placebo a…

This study tests whether duloxetine, a drug used for depression and pain, can prevent the numbness, tingling, and pain caused by the chemotherapy drug oxaliplatin in people with stage II or III colorectal cancer. About 220 participants will receive either duloxetine or a placebo …

This study tested whether taking metformin (a common diabetes drug) for 12 months could reduce abnormal breast cell growth in women at high risk for breast cancer. The 86 participants had prior breast abnormalities or strong family history. Researchers compared metformin to a pla…

This study tests whether adding text message reminders and telephone counseling helps breast cancer patients take their daily hormone therapy pills more consistently. About 1,167 women with early-stage hormone receptor-positive breast cancer will be followed for up to two years. …

This study tests a pre-surgical toolkit (OPTI-Surg) designed to help older cancer patients recover faster and better after major surgery. The toolkit provides recommendations before surgery to improve physical function and reduce complications. About 325 participants with planned…

This study compares two drugs—olanzapine and megestrol acetate—to see which works better for improving appetite and preventing weight loss in people with advanced cancer. About 227 patients will take one of the two medications for four weeks. The goal is to find a more effective …

This study looks at whether a special decision aid helps people with early-stage breast cancer feel more confident and involved when choosing their surgery. It includes over 600 patients, focusing on those with fewer resources. The goal is to see if the tool boosts patient engage…